Researchers at A*STAR’s Singapore Bioimaging Consortium (SBIC) have discovered that branched-chain amino acids (BCAAs) in tumours can be targeted to prevent and treat cancer. Together with collaborators from the United States and National Cancer Centre Singapore (NCCS), they found that some cancers potently suppress the catabolism (breakdown) of BCAAs. This leads to BCAAs accumulating in...
Tag: <span>Liver cancer</span>
Post
Mass. General-led study supports aspirin’s ability to reduce liver cancer risk
The results of a study led by Massachusetts General Hospital (MGH) investigators support evidence from previous studies suggesting the regular use of aspirin can reduce the risk of developing primary liver cancer – also called hepatocellular carcinoma (HCC). Their report analyzing data from two long-term epidemiologic studies appears in JAMA Oncology and finds that regular aspirin use...
Post
Diabetes drug may prevent liver cancer
A drug commonly used to treat type 2 diabetes might help prevent patients from developing liver cancers. Credit: CC0 Public Domain In a study published this month in the journal Cancer Causes & Control, Harvey J. Murff, MD, MPH, and colleagues found that patients taking metformin had a reduced rate of liver cancer compared to...
Post
Scientists develop novel drug that could potentially treat liver cancer more effectively
A research team led by scientists from the Cancer Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS) has developed a novel peptide drug called FFW that could potentially stop the development of hepatocellular carcinoma (HCC), or primary liver cancer. This landmark discovery opens the door for more effective treatment of liver cancer with...
Post
Cyramza Delivers New Hope for Patients with Liver CancerShare
Hepatocellular carcinoma is the most common type of primary liver cancer and is the second leading cause of cancer-related death worldwide. Treatment for liver cancer is often ineffective, prompting pharmaceutical companies to question whether medications used for other types of cancer may be useful. Eli Lilly and Company may have found a valuable contender upon...
Post
Tumor suppressor protein targets liver cancer
Salk Institute scientists, together with researchers from Switzerland’s University of Basel and University Hospital Basel, discovered a protein called LHPP that acts as a molecular switch to turn off the uncontrolled growth of cells in liver cancer. The tumor suppressor, which could be useful as a biomarker to help diagnose and monitor treatment for liver...
Post
Diabetes medicine reduces liver fat in nonalcoholic fatty liver disease
In people with type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) is common and can progress to a severe liver disease known as nonalcoholic steatohepatitis (NASH). Now a study has found that empagliflozin, a newer treatment for type 2 diabetes, reduces liver fat in patients with NAFLD and diabetes. Results of the randomized controlled study,...
Post
Can aspirin stop liver cancer in hepatitis B patients?
(HealthDay)—Daily aspirin may reduce the risk of liver cancer for people with hepatitis B infection, a new study suggests. Hepatitis B virus attacks the liver and can cause cirrhosis and liver cancer. Previous research suggests daily low-dose aspirin therapy may prevent cancer, but there is little clinical evidence on whether regular aspirin use can prevent liver cancer...
Post
People of Mexican decent in US have more liver cancer risk factors than those living in Mexico
Mexican-Americans living in the United States demonstrated more risk factors for liver cancer than their counterparts in Mexico, according to results of a study presented at the 10th AACR Conference on The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, held here Sept. 25-28. “Liver cancer incidence and mortality have been...
Post
Discovery of drug combination: Overcoming resistance to targeted drugs for liver cancer
A KAIST research team presented a novel method for improving medication treatment for liver cancer using Systems Biology, combining research from information technology and the life sciences. Professor Kwang-Hyun Cho in the Department of Bio and Brain Engineering at KAIST conducted the research in collaboration with Professor Jung-Hwan Yoon in the Department of Internal Medicine...